Abstract
Current tuberculosis (TB) treatment suffers from complexity of the dosage regimens, length of treatment, and toxicity risks. Many natural products have shown activity against drug-susceptible, drug-resistant, and latent/dormant Mycobacterium tuberculosis, the pathogen responsible for TB infections. Natural sources, including plants, fungi, and bacteria, provide a rich source of chemically diverse compounds equipped with unique pharmacological, pharmacokinetic, and pharmacodynamic properties. This review focuses on natural products as starting points for the discovery and development of novel anti-TB chemotherapy and classifies them based on their chemical nature. The classes discussed are divided into alkaloids, chalcones, flavonoids, peptides, polyketides, steroids, and terpenes. This review also highlights the importance of collaboration between phytochemistry, medicinal chemistry, and physical chemistry, which is very important for the development of these natural compounds.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 29-38 |
| Number of pages | 10 |
| Journal | Assay and Drug Development Technologies |
| Volume | 14 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2016 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Drug Discovery
Cite this
Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents. / Farah, Shrouq I.; Abdelrahman, Abd Almonem; North, E. Jeffrey; Chauhan, Harsh.
In: Assay and Drug Development Technologies, Vol. 14, No. 1, 01.01.2016, p. 29-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Opportunities and Challenges for Natural Products as Novel Antituberculosis Agents
AU - Farah, Shrouq I.
AU - Abdelrahman, Abd Almonem
AU - North, E. Jeffrey
AU - Chauhan, Harsh
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Current tuberculosis (TB) treatment suffers from complexity of the dosage regimens, length of treatment, and toxicity risks. Many natural products have shown activity against drug-susceptible, drug-resistant, and latent/dormant Mycobacterium tuberculosis, the pathogen responsible for TB infections. Natural sources, including plants, fungi, and bacteria, provide a rich source of chemically diverse compounds equipped with unique pharmacological, pharmacokinetic, and pharmacodynamic properties. This review focuses on natural products as starting points for the discovery and development of novel anti-TB chemotherapy and classifies them based on their chemical nature. The classes discussed are divided into alkaloids, chalcones, flavonoids, peptides, polyketides, steroids, and terpenes. This review also highlights the importance of collaboration between phytochemistry, medicinal chemistry, and physical chemistry, which is very important for the development of these natural compounds.
AB - Current tuberculosis (TB) treatment suffers from complexity of the dosage regimens, length of treatment, and toxicity risks. Many natural products have shown activity against drug-susceptible, drug-resistant, and latent/dormant Mycobacterium tuberculosis, the pathogen responsible for TB infections. Natural sources, including plants, fungi, and bacteria, provide a rich source of chemically diverse compounds equipped with unique pharmacological, pharmacokinetic, and pharmacodynamic properties. This review focuses on natural products as starting points for the discovery and development of novel anti-TB chemotherapy and classifies them based on their chemical nature. The classes discussed are divided into alkaloids, chalcones, flavonoids, peptides, polyketides, steroids, and terpenes. This review also highlights the importance of collaboration between phytochemistry, medicinal chemistry, and physical chemistry, which is very important for the development of these natural compounds.
UR - http://www.scopus.com/inward/record.url?scp=84979734812&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979734812&partnerID=8YFLogxK
U2 - 10.1089/adt.2015.673
DO - 10.1089/adt.2015.673
M3 - Article
C2 - 26565779
AN - SCOPUS:84979734812
VL - 14
SP - 29
EP - 38
JO - Assay and Drug Development Technologies
JF - Assay and Drug Development Technologies
SN - 1540-658X
IS - 1
ER -